Status:
COMPLETED
Meloxicam for Pain Management After Total Joint Arthroplasty (TJA)
Lead Sponsor:
University of Miami
Conditions:
Total Knee Replacement
Total Hip Replacement
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this project is to determine if a change in patient reported pain, nausea and vomiting after total knee and hip arthroplasty could be observed with the substitution of Intravenous melox...
Eligibility Criteria
Inclusion
- Patients over the age of 18,
- Patients undergoing primary total knee or primary total hip replacement at the University of Miami Hospital,
- Patients that have capacity to provide medical consent
Exclusion
- All patients under the age of 18
- Prisoners, diabetics, increased risk of bleeding, and pregnant women.
- Patients with prior surgery or history of infection on the joint of interest.
- Patients with an estimated glomerular filtration rate (eGFR) \<50 ml/min
- Patients on dialysis or renal transplant.
- Patients on steroid preoperatively.
- Allergy to sulfas
- Inability to provide medical consent.
- Any condition that, in the opinion of the investigator, would compromise the well-being of the patient or the study or prevent the patient from meeting or performing study requirements will exclude the participant.
Key Trial Info
Start Date :
May 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2023
Estimated Enrollment :
223 Patients enrolled
Trial Details
Trial ID
NCT05291598
Start Date
May 1 2022
End Date
May 1 2023
Last Update
August 14 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Miami
Miami, Florida, United States, 33136